Compare Bristol-Myers Squibb Co (BMY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Omnicom Group Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Omnicom Group Inc. trades at $84.63 (market cap $23.58B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.5× Omnicom Group Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | OMC | |
|---|---|---|
Market Cap | $129.94B | $23.58B |
Sector | Health | Media |
52-Week High | $65.89 | $86.22 |
52-Week Low | $42.60 | $67.27 |
Enterprise Value | $163.92B | $31.66B |
Dividend Yield | 3.96% | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Omnicom Group (OMC) trades at $84.65, down 0.69% on the day, with a bullish technical outlook per moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with $2.65 EPS, driven by 6.1% organic revenue growth and margin expansion post-Interpublic acquisition. The company maintains a 4% dividend yield and active buybacks, though high P/E of 232.3 reflects net income volatility.
Outlook is positive with analyst consensus target of $107.00 (27% upside), but risks include integration costs, debt increase, and competitive pressures. The stock offers value from synergy realization and AI-driven growth initiatives, yet investors must monitor execution on cost savings and organic growth sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
